<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673799</url>
  </required_header>
  <id_info>
    <org_study_id>KYJT-MV088-I01</org_study_id>
    <secondary_id>CTR20202419</secondary_id>
    <nct_id>NCT04673799</nct_id>
  </id_info>
  <brief_title>Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.</brief_title>
  <official_title>A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kunming Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kunming Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetics,&#xD;
      Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, double center, randomized, double-blind, single dose and parallel group&#xD;
      clinical trial . The primary objective is to assess the pharmacokinetic similarity of MV088&#xD;
      and Prolia® in healthy volunteers. The secondary objectives is to assess the similarity of&#xD;
      clinical safety and immunogenicity of MV088 and Prolia® in healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 22, 2021</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized、double-blind、parallel-group、single-dosed、positive control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: Cmax</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#Cmax of MV088/Prolia after the first day administer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: AUC0-∞</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#AUC0-∞ of MV088/Prolia after the first day administer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: AUC0-t</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#AUC0-t of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: Tmax</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#Tmax of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: t1/2</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#t1/2 of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: CLz/F</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#CLz/F of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: Vz/F</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#Vz/F of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MV088/Prolia in plasma: λz</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the pharmacokinetic parameters#λz of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation of MV088/Prolia</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the Safety evaluation of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity evaluation of MV088/Prolia</measure>
    <time_frame>126 days</time_frame>
    <description>To characterize the Immunogenicity evaluation of MV088/Prolia after the first day administer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MV088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV088 injection (60mg) by subcutaneous injection once on the first day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolia®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolia® injection (60mg) by subcutaneous injection once on the first day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MV088 injection</intervention_name>
    <description>MV088 injection (60mg) by subcutaneous injection once on the first day</description>
    <arm_group_label>MV088</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolia® injection</intervention_name>
    <description>Prolia® injection (60mg) by subcutaneous injection once on the first day</description>
    <arm_group_label>Prolia®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years or ≤65 years, male(including the boundary value).&#xD;
&#xD;
          2. The body weight is within the range of 50~70kg (including the boundary value) and the&#xD;
             body mass index（BMI） is within the range of 19.0~26.0kg/m2 (including the boundary&#xD;
             value).&#xD;
&#xD;
          3. Sign the informed consent form and fully understand the test content, process and&#xD;
             possible adverse reactions, and be able to complete the study according to the test&#xD;
             plan requirements.&#xD;
&#xD;
          4. The volunteers are able to communicate well with the researchers, understand and&#xD;
             comply with the requirements of the study, and are expected to participate in all&#xD;
             follow-up visits (no long-term plans to leave the study site).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have participated in any drug or medical device trials or are participating in other&#xD;
             clinical trials within 3 months prior to first administration.&#xD;
&#xD;
          2. Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.&#xD;
&#xD;
          3. The dental or jaw disease that is active, requiring oral surgery; or planned for&#xD;
             invasive dental surgery during the study; or dental or oral surgery wounds have not&#xD;
             healed.&#xD;
&#xD;
          4. Occurred or suffering hypocalcemia.&#xD;
&#xD;
          5. Have taken any medicine (including Chinese herbal medicine) within 14 days before the&#xD;
             first administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Li, ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Hospital of Changsha</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianchang He, ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yunnan Provincial Hospital of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duo Gao</last_name>
    <phone>008613032237118</phone>
    <email>duo.gao@kpc.com.cn</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

